Retatrutide
Metabolic & Weight ManagementTriple agonist (GIP/GLP-1/Glucagon) representing the next generation of weight loss peptides with remarkable efficacy.
Key Benefits
- ✓Exceptional weight loss (24%+)
- ✓Enhanced fat oxidation via glucagon
- ✓Improved insulin sensitivity
- ✓Better glucose control
- ✓Increased energy expenditure
- ✓Preserved or increased lean mass
Dosing Information
Detailed Protocol
Administered via subcutaneous injection once weekly. Dosing titration from 4mg to 12mg over several months. Currently in phase 3 clinical trials.
About Retatrutide
Retatrutide is a novel triple receptor agonist that activates GIP, GLP-1, and glucagon receptors. This triple action provides enhanced fat mobilization through glucagon activity while maintaining the appetite suppression and metabolic benefits of GIP/GLP-1 activation. Clinical trials show up to 24% weight loss at 48 weeks.
Research Notes
Phase 2 trials showed 24.2% weight loss at 48 weeks with the 12mg dose. Phase 3 trials ongoing with FDA approval expected in 2025-2026. Represents significant advancement over dual agonists.
Potential Side Effects
- •Nausea and vomiting
- •Diarrhea
- •Constipation
- •Potential heart rate elevation
- •Injection site reactions
Always consult with a healthcare professional before starting any peptide therapy.